




ICMA European Repo & Collateral  
Council (ERCC) General Meeting  
*Impact of Regulation on Repo*

27 September 2016

Michael Manna, Head of FI Financing Trading, Europe

# The Regulatory Pendulum: Direction of Travel?

Following the events of 2008 there was little doubt the regulatory pendulum would swing in the direction of a more uncompromising application of regulation in order to promote macro prudential stability. New regulation was written against the back drop of a caustic political environment, with the then available evidence, and with no credible ability to fully assess its impact. Eight years later we have new facts, we're starting to observe unintended consequences, and regulators are asking questions. Is there enough evidence to support delaying the regulatory pipeline and/or recalibrate existing rules?  
*Is the pendulum moving towards equilibrium?*



1. Bank of England, Financial Stability Report, July 2016, Issue No.39.

# BCBS268 Proposed Revisions to the Basel III Leverage Ratio

## Highlights from the Consultation

### Settlement Balances

- Most European banks adopt a trade date accounting approach which recognizes or derecognizes trading portfolio items bought and sold on trade date –i.e. cash execution activity.
- However, these trades do not settle until a few days later, e.g.T+2. As a result, IFRS accounting rules provide that a “settlement liability” (in the case of a security purchase) or a “settlement asset” (in the case of a security sale) is recognised for the cash payable /receivable between trade date and settlement date. BCBS consultation is seeking harmonisation with the US approach, no change in the accounting principles but even out in the leverage exposure measure.
- *US GAAP allows brokers to net down these settlement balances to a single item regardless of isin, counterparty, currency, etc.*

### Secure Funding Transactions (SFTs)

- Basel proposed that open trades cannot net because they do not meet the criteria of having an explicit settlement date, but they request further evidence of the adverse impact of this treatment on open repos and any arguments for why further revisions may be warranted.
- Not addressed in this consultation:
  - In the E-C add-on for SFTs, there is a double count for cash collateralised stock borrow where the haircut is on the accounting balance sheet and double counted in the leverage exposure via the E-C add on.
  - Clarification around treatment of Forward Starting Reverse Repos.

### Derivatives RC and PFE – ‘Big Help to Client Swap Clearing Banks’

- The PFE add-on - Basel proposes replacing CEM with SA-CCR however, the PFE cannot be reduced for any collateral posted by the counterparty or any negative mark-to-market of the derivative.
- Replacement Cost - Basel also proposes the SA-CCR calculations.

# Regulators Searching for Reasons Allocation of Capital: Further Understanding is Needed

---

*“In principle, leverage ratio requirements, as currently calibrated, would constrain only firms with relatively low risk-weighted assets on average. The impact will also depend on the business level at which it is applied. For the UK leverage ratio framework, this is currently at the consolidated level only”<sup>(2)</sup>*

*“However, if the leverage ratio were viewed as binding on individual business lines, this may create incentives for a dealer to increase margins, or reduce volumes, on lower-risk activities such as repo (Duffie 2016).<sup>(1)</sup>”*


*“Nevertheless, there is some market and supervisory intelligence that dealers are considering the marginal impact of a leverage ratio requirement at the level of individual business lines when making decisions about how to allocate balance sheet to different activities”<sup>(2)</sup>*

*“As set out in the Review of the FPC Direction on a leverage ratio requirement and buffers chapter, in the light of evidence of declining market liquidity in some core financial markets and of a decline in availability of repo financing, which supports market functioning more broadly, the FPC is restating its intention for its leverage ratio framework to be applied at consolidated level and not to individual activities”<sup>(2)</sup>*

1. Duffie, D (2016), ‘Submission in response to US Treasury Notice seeking public comment on the evolution of the Treasury Market structure’; [www.darrellduffie.com/uploads/policy/DuffieTreasuryRFIApril2016.pdf](http://www.darrellduffie.com/uploads/policy/DuffieTreasuryRFIApril2016.pdf).
2. Bank of England, Financial Stability Report, July 2016, Issue No.39.

# Understanding Capital Allocation: a Top Down Process

*Strengthening the weakest links*




In the past business lines were allocated a revenue budget, influencing their behavior and decisions. Post 2008, revenue remains important but the focus has turned to risk & leverage. Which forms the foundation for how a banks’ performance and stability is measured and assessed. Allocating financial resource to individual business lines forces them to either seek efficiencies and/or amend their business model to address their weaker return metric. This can include increasing prices or simply reducing activity to bring down the use of capital.

# Assessing the Leverage Ratio: Blunt and Blind

Basel III is actually very simple.

Everything is about CAPITAL, the good stuff, loss absorbing, and expensive to raise. The amount of capital a bank holds will influence both the size and shape of businesses that can be supported. Businesses will be measured against their use of capital by both: how much they need to support required leverage and / or the amount of risk it takes.



# Repo Returns Under Leverage Returns (RoLBS)?

Assumptions	
BCBS 270 Balance Sheet	£1bln
PnL Flat 1YR Run Rate	100bp
Operating Assumptions <sup>(1)</sup>	
Cost / Income (C/I) Ratio	55%
Tax Rate	35%

How much capital does a bank need to support £1bln of Repo?

$$4\% = \frac{X}{£1bln} \longrightarrow X = £40m$$

How much gross revenue do I generate?

$$£1bln \times 100bp = £10m$$

What is my NET revenue?

PBT:  $£10m - C/I \text{ Ratio} = £4.5m$       Net Income:  $£4.5m - 35\% \text{ Tax Rate} = £2.925m$

What do my Repo returns on leverage balance sheet look like?

Return on Leverage Balance Sheet (LBS)

Gross	PBT <sup>(2)</sup>	NET
$\frac{£10m}{£40m} = 25\%$	$\frac{£4.5m}{£40m} = 11.25\%$	$\frac{£2.925m}{£40m} = 7.32\%$

1. Note: Figures illustrative ONLY.  
 2. PBT = Pre Tax Profit.

# Repo Returns Under Capital (RoRWA)?

Assumptions	
BCBS 270 Balance Sheet	£1bln
PnL Flat 1YR Run Rate	100bp
Counterparty Risk Weight (CP-RW)	100%
FCCM Volatility Adjustment Haircut*	7% <sup>(2)</sup>
Hair Cut Applied to Client Trades	0%
Operating Assumptions <sup>(2)</sup>	
Cost / Income Ratio	55%
Tax Rate	35%

How many RWA's are produced with the given trade assumption?

$$\begin{aligned} \text{RWA} &= \text{EAD} \times \text{CPRW} \\ \text{EAD: } &£1\text{bln} \times 7\% = 70\text{m} \\ \text{CPRW: } &100\% \\ \text{RWA} &= 70\text{m} \end{aligned}$$

How much capital do I need to support 70mln of RWA?

$$11\% = \frac{X \times 70\text{m}}{£} \longrightarrow X = £7.7\text{m}$$

How much gross revenue do I generate?

$$£1\text{bln} \times 100\text{bp} = £10\text{m}$$

What is my NET revenue?

$$\text{PBT: } £10\text{m} - \text{C/I Ratio} = £4.5\text{mln}$$

$$\text{Net Income: } £4.5 - \text{Tax} = £2.925\text{m}$$

What do my returns based on RWA exposure look like?

Return on RWA		
Gross	PBT	NET
$\frac{£10\text{m}}{£7.7\text{m}} = 130\%$	$\frac{£4.5\text{m}}{£7.7\text{m}} = 58\%$	$\frac{£2.925\text{m}}{£7.7\text{m}} = 38\%$

1. Note: Figures are illustrative ONLY.

2. Source: <http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2013:176:0001:0337:EN:PDF> Figure is a blended Rate to simply illustrate and example.

# Repo Returns Under Leverage Returns with an Asset Class & Activity Discount (RoLBS)?

## Assumptions

BCBS 270 Balance Sheet £1bln

PnL Flat 1YR Run Rate 100bp

Apply an Asset Class & Activity Discount to the Leverage Exposure 50%

## Operating Assumptions<sup>(1)</sup>

Cost / Income (C/I) Ratio 55%

Tax Rate 35%

How much capital does a bank need to support £1bln of Gov't Repo?

$$4\% = \frac{X}{£1bln} \longrightarrow X = £40m$$

Apply a 50% LR 'discount' for Gov't Repo?

$$2\% = \frac{X}{£1bln} \longrightarrow X = £20m$$

How much gross revenue do I generate?

$$£1bln \times 100bp = £10m$$

What is my NET revenue?

$$\text{PBT: } £10m - \text{C/I Ratio} = £4.5m$$

$$\text{Net Income: } £4.5m - 35\% \text{ Tax Rate} = £2.925m$$

What do my Repo returns on leverage balance sheet look like?

Return on Leverage Balance Sheet (LBS)

Gross

$$\frac{£10m}{£20m} = 50\%$$

PBT<sup>(2)</sup>

$$\frac{£4.5m}{£20m} = 22.5\%$$

NET

$$\frac{£2.925m}{£20m} = 14.6\%$$

1. Note: Figures illustrative ONLY.

2. PBT = Pre Tax Profit.


# Proposed Changes will help but Might not be Enough

The FPC's recommend adjustments to the Leverage Ratio will have a positive effect in reducing the leverage exposure measure footprint for STFs and cash trading. What it doesn't change is the actual quantum or cost of capital needed to support these activities. Recalibrating the overall leverage ratio target could be one solution but may have undesirable effects. A more targeted approach maybe to apply a leverage measure discount, which considers activities and asset classes that are vital to macro prudential stability.

## Comparing the Return Outcomes to 12% Return on Equity Target

REE Metrics	Results	Pass/Fail Return Hurdle
Return of LBS (RoLBS)	7.3%	✗
Return of Capital (RoRWA)	38%	✓
Discounted Return of LBS (RoLBS)	14.6%	✓

✗ Fail    ✓ Pass



Margin Requirement for Uncleared Derivatives:  
*The wait is Finally Over*

---

# Increased Demand for Collateral but How Much?

Even though the regulatory decision is still pending regarding which risk model can be used to calculate the required initial margin, an important aspect, which will have a large influence is the fact that the collateral will be segregated and cannot be rehypothecated. This will have a lasting effect on its availability and price.

## Bi-lateral Margin Requirements      Cleared Product CCP Margin Requirements



## Estimated Collateral Requirements<sup>(1)</sup>




## Non-Cleared Product Segregated IA

Businesses will gain a benefit though reduced capital requirements (RWA) but will be introduced to new costs and the relationship between collateral and balance sheet, which will unless they can increase revenue, have a drag on their RoE




1. Source: Barclays Estimates.

# Collateral Demand: Have we Considered Everything?




# Collateral Demand: Only Time will Tell.....



## Successful Product and Service Evolution

- Results in:
- Activity levels decrease and/or innovation takes root
  - Both outcomes reduces the need for capital to support exposure and improves the return profile
  - Less exposure, requires less collateralization
  - The reduced need to collateralize exposure leads to reduced demand for collateral
  - So how accurate are the forecasts for collateral?

## Collateral Forecasting



# Sales and Trading Commentary Disclaimer

---

**CONFLICTS OF INTEREST** BARCLAYS IS A FULL SERVICE INVESTMENT BANK. In the normal course of offering investment banking products and services to clients. Barclays may act in several capacities (including issuer, market maker, underwriter, distributor, index sponsor, swap counterparty and calculation agent) simultaneously with respect to a product, giving rise to potential conflicts of interest which may impact the performance of a product.

**NOT RESEARCH** This document is from a Barclays Trading and/or Distribution desk and is not a product of the Barclays Research department. Any views expressed may differ from those of Barclays Research.

**BARCLAYS POSITIONS** Barclays, its affiliates and associated personnel may at any time acquire, hold or dispose of long or short positions (including hedging and trading positions) which may impact the performance of a product.

**FOR INFORMATION ONLY** THIS DOCUMENT IS PROVIDED FOR INFORMATION PURPOSES ONLY AND IT IS SUBJECT TO CHANGE. IT IS INDICATIVE ONLY AND IS NOT BINDING.

**NO OFFER** Barclays is not offering to sell or seeking offers to buy any product or enter into any transaction. Any transaction requires Barclays' subsequent formal agreement which will be subject to internal approvals and binding transaction documents. Without limitation to the foregoing, any transaction may also be subject to review by Barclays against its published Tax Principles.

**NO LIABILITY** Barclays is not responsible for the use made of this document other than the purpose for which it is intended, except to the extent this would be prohibited by law or regulation.

**NO ADVICE** OBTAIN INDEPENDENT PROFESSIONAL ADVICE BEFORE INVESTING OR TRANSACTING. Barclays is not an advisor and will not provide any advice relating to a product. Before making an investment decision, investors should ensure they have sufficient information to ascertain the legal, financial, tax and regulatory consequences of an investment to enable them to make an informed investment decision.

**THIRD PARTY INFORMATION** Barclays is not responsible for information stated to be obtained or derived from third party sources or statistical services.

**PAST & SIMULATED PAST PERFORMANCE** Any past or simulated past performance (including back-testing) contained herein is no indication as to future performance.

**OPINIONS SUBJECT TO CHANGE** All opinions and estimates are given as of the date hereof and are subject to change. Barclays is not obliged to inform investors of any change to such opinions or estimates.

**NOT FOR RETAIL** This document is being directed at persons who are professionals and is not intended for retail customer use.

**IMPORTANT DISCLOSURES** For important regional disclosures you must read, click on the link relevant to your region. Please contact your Barclays representative if you are unable to access.

**EMEA** <http://group.barclays.com/disclosures/emea-disclosures>

**APAC** <http://group.barclays.com/disclosures/apac-disclosures>

**U.S.** <http://group.barclays.com/disclosures/us-disclosures>

**IRS CIRCULAR 230 DISCLOSURE:** Barclays does not provide tax advice. Please note that (i) any discussion of US tax matters contained in this communication (including any attachments) cannot be used by you for the purpose of avoiding tax penalties; (ii) this communication was written to support the promotion or marketing of the matters addressed herein; and (iii) you should seek advice based on your particular circumstances from an independent tax advisor.

**CONFIDENTIAL** This document is confidential and no part of it may be reproduced, distributed or transmitted without the prior written permission of Barclays.

**ABOUT BARCLAYS** Barclays offers premier investment banking products and services to its clients through Barclays Bank PLC. Barclays Bank PLC is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority and is a member of the London Stock Exchange. Barclays Bank PLC is registered in England No. 1026167 with its registered office at 1 Churchill Place, London E14 5HP.

**COPYRIGHT** © Copyright Barclays Bank PLC, 2016 (all rights reserved).